Back

Cohort studies on melanoma and keratinocyte skin cancer: a systematic review

Olsen, C.; Whiteman, D. C.; Neale, R. E.

2025-08-15 epidemiology
10.1101/2025.08.13.25332927
Show abstract

The incidence of cutaneous malignancies is increasing worldwide, presenting an important public health burden. Cohort studies can provide high quality data on the epidemiology of these cancers, and are invaluable for deriving measures of disease burden used to inform prevention, diagnosis and treatment. We conducted a systematic review of the literature to summarise the characteristics of cohort studies that have published one or more papers describing the epidemiology of melanoma and/or keratinocyte cancers. Eligible studies were population-based cohort studies that have published findings on incidence or etiology of melanoma or keratinocyte cancer (including associations with phenotypic, environmental, and genetic factors). We excluded clinical cohorts focused on survivorship outcomes. We searched MEDLINE 1950 (U.S. National Library of Medicine, Bethesda, MD, USA), the ISI Science Citation Index (1990 to 31 July 2025) and the reference lists of retrieved articles, imposing no language restrictions. We identified 22 eligible cohort studies, 20 of which had published on melanoma, and 16 on keratinocyte cancer. Nine were conducted in the United States, eleven in Europe, and two in Australia. There was substantial variability in terms of cohort size, risk factor information recorded at baseline, and other data collected (e.g., health services, genetic). Only three studies were specifically designed to examine skin cancers as study endpoints, and only two cohorts pre-specified both melanoma and keratinocyte cancer endpoints. Our summary provides a resource for skin cancer researchers conducting investigations into the causes, burden and prevention of these important cancers.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
JNCI: Journal of the National Cancer Institute
based on 13 papers
Top 0.1%
12.4%
2
PLOS ONE
based on 1737 papers
Top 59%
7.5%
3
International Journal of Cancer
based on 18 papers
Top 0.2%
7.5%
4
Cancer Epidemiology, Biomarkers & Prevention
based on 14 papers
Top 0.3%
5.2%
5
British Journal of Cancer
based on 22 papers
Top 0.9%
4.6%
6
eLife
based on 262 papers
Top 5%
4.6%
7
Cancers
based on 57 papers
Top 4%
2.8%
8
BMC Cancer
based on 21 papers
Top 2%
2.8%
9
BMC Public Health
based on 148 papers
Top 12%
2.3%
10
Clinical Infectious Diseases
based on 219 papers
Top 12%
2.2%
50% of probability mass above
11
Scientific Reports
based on 701 papers
Top 66%
2.2%
12
Nature Communications
based on 483 papers
Top 29%
1.8%
13
Frontiers in Medicine
based on 99 papers
Top 10%
1.7%
14
BMJ Open
based on 553 papers
Top 45%
1.3%
15
Breast Cancer Research
based on 11 papers
Top 1.0%
1.3%
16
JAMA Network Open
based on 125 papers
Top 14%
1.3%
17
BMC Infectious Diseases
based on 110 papers
Top 18%
0.8%
18
American Journal of Epidemiology
based on 54 papers
Top 6%
0.8%
19
Cancer Medicine
based on 17 papers
Top 4%
0.7%
20
Emerging Infectious Diseases
based on 84 papers
Top 13%
0.7%
21
International Journal of Infectious Diseases
based on 115 papers
Top 20%
0.7%
22
Open Forum Infectious Diseases
based on 124 papers
Top 12%
0.7%
23
PLOS Genetics
based on 39 papers
Top 6%
0.7%
24
BMC Medicine
based on 155 papers
Top 26%
0.7%
25
BMJ Health & Care Informatics
based on 13 papers
Top 4%
0.7%